Harvard Bioscience (HBIO) Amortizatization of Intangibles (2017 - 2026)
Harvard Bioscience (HBIO) posted quarterly Amortizatization of Intangibles of $907000.0 for Q1 2026, down 24.67% year-over-year from $1.2 million in Q1 2025, and up 1.68% quarter-over-quarter from $892000.0 in Q4 2025.
Harvard Bioscience (HBIO) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Amortizatization of Intangibles for 10 consecutive years, with $907000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 24.67% year-over-year to $907000.0; the TTM figure through Mar 2026 stood at $3.9 million (down 25.33% YoY), while the FY2025 annual figure was $4.2 million, down 22.22% from the prior year.
- Amortizatization of Intangibles improved to $907000.0 in Q1 2026 per HBIO's latest filing, from $892000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.6 million in Q4 2022 and bottomed at $892000.0 in Q4 2025.
- Historically, Amortizatization of Intangibles has averaged $1.3 million across 5 years, with a median of $1.4 million in 2024.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles climbed 12.26% — and 2025, when it tumbled 34.76%.
- Harvard Bioscience's Amortizatization of Intangibles stood at $1.6 million in 2022, then retreated by 16.44% to $1.4 million in 2023, then dropped by 6.68% to $1.3 million in 2024, then dropped by 29.82% to $892000.0 in 2025, then increased by 1.68% to $907000.0 in 2026.
- Business Quant data shows HBIO's Amortizatization of Intangibles at $907000.0 in Q1 2026, $892000.0 in Q4 2025, and $899000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 38.80 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | - |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 10.34 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 500,000.00 |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | - |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | - |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | - |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn | 908,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 908,000.00 |
| Jun 30, 2026 | 908,000.00 |
| Mar 31, 2026 | 907,000.00 |
| Mar 31, 2026 | 907,000.00 |
| Dec 31, 2025 | 892,000.00 |
| Dec 31, 2025 | 892,000.00 |
| Sep 30, 2025 | 899,000.00 |
| Sep 30, 2025 | 899,000.00 |
| Jun 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.38 Mn |